{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=27",
    "query": {
      "intervention": "Part 1",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 6233,
    "total_pages": 624,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T14:59:16.828Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02819726",
      "title": "PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "SAIT101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MabThera",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituxan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Archigen Biotech Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 294,
      "start_date": "2016-10-11",
      "completion_date": "2018-11-07",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 15,
      "location_summary": "Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819726"
    },
    {
      "nct_id": "NCT03770689",
      "title": "Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Peposertib 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Peposertib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Peposertib 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Peposertib 250 mg",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2019-03-20",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03770689"
    },
    {
      "nct_id": "NCT05187624",
      "title": "A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "RO7428731",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2022-04-05",
      "completion_date": "2025-05-14",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05187624"
    },
    {
      "nct_id": "NCT03198780",
      "title": "Mindful Breathing Awareness Through Pursed-Lip Breathing Training",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Breathing Awareness",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Minnesota HealthSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-10-01",
      "completion_date": "2019-07-31",
      "has_results": false,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03198780"
    },
    {
      "nct_id": "NCT00895960",
      "title": "Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "CNS Disease",
        "Brain Diseases"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "RT (Radiotherapy)",
          "type": "RADIATION"
        },
        {
          "name": "TMZ (Temozolomide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2009-05-07",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895960"
    },
    {
      "nct_id": "NCT05380323",
      "title": "A Study of LY3541105 in Healthy and Overweight Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3541105",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 206,
      "start_date": "2022-05-10",
      "completion_date": "2024-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • San Antonio, Texas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05380323"
    },
    {
      "nct_id": "NCT03956680",
      "title": "An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Cancers"
      ],
      "interventions": [
        {
          "name": "BMS-986301",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2019-03-26",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03956680"
    },
    {
      "nct_id": "NCT05514496",
      "title": "A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "NX-019",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nalo Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2022-10-05",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514496"
    },
    {
      "nct_id": "NCT02214121",
      "title": "A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Ticagrelor Dose 1a + Dose 2a",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor Dose 1b + Dose 2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 46,
      "start_date": "2014-09-11",
      "completion_date": "2017-02-27",
      "has_results": true,
      "last_update_posted_date": "2018-12-14",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 6,
      "location_summary": "Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214121"
    },
    {
      "nct_id": "NCT01714440",
      "title": "Genomics of Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "KidneyTransplant Recipients",
        "Simultaneous Kidney/Pancreas Recipients",
        "Kidney Transplant Donor"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1552,
      "start_date": "2012-08",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-11-13T14:59:16.828Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01714440"
    }
  ]
}